Pressmeddelande -
Oscillution enters major pharma collaboration
..............................................................
GU Ventures share news and information about the business, its companies, and alumni companies:
..............................................................
Oscillution, a GU Ventures company, has developed an innovative platform that measures how human brain cells respond to drugs in the lab – helping reveal effects that traditional methods often miss. Now we are pleased to announce that Oscillution has now entered into a major commercial project with a leading global pharmaceutical company in the CNS (Central Nervous System) space.
Building on previous work and collaborations, this engagement represents a step forward in applying Oscillution’s platform earlier in the drug discovery process — supporting pharma teams in identifying better treatments for CNS disorders from the outset.
By enabling human-relevant brain activity measurements in vitro, Oscillution helps uncover functional drug effects that other assays miss.
CNS drug development remains one of the toughest areas in pharma, with high failure rates and limited predictive models. Solutions that provide earlier, more accurate functional insights are increasingly critical.
"We’re excited to see Oscillution deepen its industry collaborations and expand the use of its technology in real-world drug development programs. If you're an investor or partner interested in the future of CNS drug discovery, we’d love to connect", says Daniel Poté, Business Developer GU Ventures.
"Understanding the function of the human brain is crucial for the future of CNS drug development. This collaboration reflects a broader shift toward analyses where human brain cells exhibit the brain’s electrical signals—an approach that, despite its clear relevance, has not yet been fully leveraged to develop better treatments. At Oscillution, we are committed to driving this paradigm shift forward by enabling deeper functional insights earlier in the development process, thereby contributing to more effective and predictable treatments for patients”, says Sebastian Illes, CEO Oscillution
Oscillution provides innovative services to pharmaceutical and biotech companies, by creating functional human brain cells and integrating them with sensor chips to uncover drug effects on brain function that traditional methods cannot detect.
The company strives to create a future where the impact of every drug on human brain function is fully understood before it reaches patients.
Impact: By providing deeper insights into the effects of pharmaceuticals on the human brain, the company contributes to safer, more effective treatments while reducing the reliance on animal testing. This ultimately leads to improved patient outcomes and a more ethical approach to drug discovery.
Adressing United Nations Sustainable Development Goal (SDG): Goal 3
For more information, please visit: https://www.oscillution.com/
Ämnen
Kategorier
Regioner
Om GU Ventures AB
GU Ventures bygger företag av banbrytande idéer som kan forma en bättre morgondag och är topprankad av UBI Global Index som en av världens 20 ledande universitetsdrivna inkubatorer. Vi finansierar och utvecklar nya innovativa affärsidéer med kopplingar till Göteborgs universitet, som är ett av norra Europas största universitet. Vårt uppdrag är att kommersialisera dessa innovationer, så att det leder till användning av forskning och kompetens, förnyelse av näringslivet, skapande av jobb och hållbar tillväxt. Vårt passionerade team av företagsbyggare, finansexperter, IP och juridisk talang supporterar dedikerat våra företag och säkerställer deras framgång.
Sedan startpunkten 1995 har GU Ventures utvecklat över 240 nya affärsidéer, varav 140 bedriver verksamhet idag och varav 15 är listade. Vår portfölj består av 80-tal innehav och ett antal projekt.
I den senaste undersökningen matchar 87% av företagen de globala hållbarhetsmål som ställts av FN. GU Ventures ägs helt av den svenska staten och förvaltas av Göteborgs universitet. Läs gärna mer på: www.guventures.com.
